Bessemer Group
RYTM icon

Bessemer Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bessemer Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Hold
30
– – ﹤0.01% 2363
2026
Q1 		$3K Sell
30
-36
-55% -$3.5K ﹤0.01% 2331
2025
Q4 		$7K Hold
66
– – ﹤0.01% 2194
2025
Q3 		$7K Hold
66
– – ﹤0.01% 2066
2025
Q2 		$4K Hold
66
– – ﹤0.01% 2088
2025
Q1 		$4K Buy
66
+36
+120% +$2K ﹤0.01% 2109
2024
Q4 		$2K Hold
30
– – ﹤0.01% 2262
2024
Q3 		$2K Buy
+30
New +$1.44K ﹤0.01% 2261
2022
Q2 		– Sell
-251
Closed -$3K – 2011
2022
Q1 		$3K Hold
251
– – ﹤0.01% 1693
2021
Q4 		$3K Hold
251
– – ﹤0.01% 1731
2021
Q3 		$3K Hold
251
– – ﹤0.01% 1586
2021
Q2 		$5K Hold
251
– – ﹤0.01% 1431
2021
Q1 		$5K Buy
+251
New +$7.28K ﹤0.01% 1399
2020
Q3 		– Sell
-86,359
Closed -$1.93M – 1619
2020
Q2 		$1.93M Buy
86,359
+46,500
+117% +$906K 0.01% 498
2020
Q1 		$607K Buy
+39,859
New +$714K ﹤0.01% 734

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bessemer Group's RYTM Position: Q2 2026 in Review

Bessemer Group held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 30 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

Bessemer Group first reported a position in RYTM in Q1 2020 and has held it in 15 quarters since. The position peaked at $1.93M in Q2 2020. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Bessemer Group held 30 shares of Rhythm Pharmaceuticals worth $3K as of Q2 2026.
  • Bessemer Group left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2363 holding.
  • Bessemer Group first reported a position in Rhythm Pharmaceuticals in Q1 2020 and has held it in 15 quarters since.
  • Bessemer Group's Rhythm Pharmaceuticals position peaked at $1.93M in Q2 2020.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.